Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders

Journal of the Neurological Sciences

Volumn 323, Issue 1-2, 2012, Pages 178-182

  De, Tanima ^a   Prabhakar, Puttachandra ^a   Nagaraja, Dindagur ^a   Christopher, Rita ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Asian Indians; Cerebral venous thrombosis risk; JAK2V617F mutation

Indexed keywords

JANUS KINASE 2;

ADULT; ARTICLE; CEREBRAL SINUS THROMBOSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SMOKING;

ADULT; AGE DISTRIBUTION; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; ETHNIC GROUPS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDIA; JANUS KINASE 2; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; PREVALENCE; RISK; SEX DISTRIBUTION; SINUS THROMBOSIS, INTRACRANIAL; SMOKING; THROMBOPHILIA; YOUNG ADULT;

EID: 84867842304     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.09.012     Document Type: Article

References (40)

1. C. Prakash, and B.C. Bansal Cerebral venous thrombosis J Indian Acad Clin Med 5 1 2000 55 61
2. M.G. Bousser, and J.M. Ferro Cerebral venous thrombosis: an update Lancet Neurol 6 2 2007 162 170
3. M.G. Bousser Cerebral venous thrombosis: diagnosis and management J Neurol 247 4 2000 252 258
4. V. De Stefano, G. Finazzi, and P.M. Mannucci Inherited thrombophilia: pathogenesis, clinical syndromes, and management Blood 87 9 1996 3531 3544
5. G. Godeneche, N. Gaillard, L. Roy, A. Mania, S. Tondeur, and J.C. Chomel JAK2 V617F mutation associated with cerebral venous thrombosis: a report of five cases Cerebrovasc Dis 29 2 2010 206 209
6. A. Tefferi, and M. Elliott Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F Semin Thromb Hemost 33 4 2007 313 320
7. E.J. Baxter, L.M. Scott, P.J. Campbell, C. East, N. Fourouclas, and S. Swanton Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 9464 2005 1054 1061
8. C. James, V. Ugo, J.P. Le Couedic, J. Staerk, F. Delhommeau, and C. Lacout A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 7037 2005 1144 1148
9. B. Cheung, D. Radia, P. Pantelidis, G. Yadegarfar, and C. Harrison The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia Br J Haematol 132 2 2006 244 245
10. G.C. Wong, G.L. Kam, and E.S. Koay JAK2 mutations in Asian patients with essential thrombocythaemia Intern Med J 41 2 2011 191 196
11. Y. Chait, B. Condat, D. Cazals-Hatem, P. Rufat, S. Atmani, and D. Chaoui Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis Br J Haematol 129 4 2005 553 560
12. A.L. Basquiera, A.H. Tabares, N. Soria, M. Salguero, R. Ryser, and J.J. Garcia Prevalence of Janus kinase 2 mutations in patients with unusual site venous thrombosis Medicina (B Aires) 71 4 2011 313 316
13. S.G. Xavier, T. Gadelha, S.M. Rezende, I.R. Zalcberg, and N. Spector JAK2V617F mutation in patients with thrombosis: to screen or not to screen? Int J Lab Hematol 33 2 2011 117 124
14. S. Bellucci, B. Cassinat, N. Bonnin, C. Marzac, and I. Crassard The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder Thromb Haemost 99 6 2008 1119 1120
15. A. Tefferi Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era Hematology Am Soc Hematol Educ Program 2006 240 245
16. J. Sambrook, E.F. Fritsch, and T. Maniatis 2nd ed. Molecular cloning: a laboratory manual vol 1 1989 Cold Spring Harb Lab New York 6.4 6.11
17. D.P. Steensma, G.W. Dewald, T.L. Lasho, H.L. Powell, R.F. McClure, and R.L. Levine The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes Blood 106 4 2005 1207 1209
18. J. Stam Thrombosis of the cerebral veins and sinuses N Engl J Med 352 17 2005 1791 1798
19. D. Colaizzo, L. Amitrano, L. Iannaccone, P. Vergura, F. Cappucci, and E. Grandone Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings J Med Genet 44 6 2007 412 416
20. D. Rossi, S. Cresta, T. Destro, C. Vendramin, S. Bocchetta, and L. De Paoli JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia Br J Haematol 138 6 2007 813 814
21. V. De Stefano, A. Fiorini, E. Rossi, T. Za, G. Farina, and P. Chiusolo Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders J Thromb Haemost 5 4 2007 708 714
22. V. De Stefano, E. Rossi, T. Za, P. Chiusolo, and G. Leone The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal Thromb Haemost 99 6 2008 1121
23. S.G. Xavier, T. Gadelha, R. Schaffel, L. Britto, G. Pimenta, and D.D. Ribeiro Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis Blood Coagul Fibrinolysis 19 5 2008 468 469
24. S.M. Passamonti, E. Biguzzi, M. Cazzola, F. Franchi, F. Gianniello, and P. Bucciarelli JAK2 (V617F) mutation in patients with cerebral venous thrombosis J Thromb Haemost 10 6 2012 998 1003
25. F. Dentali, A. Squizzato, L. Brivio, L. Appio, L. Campiotti, and M. Crowther JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis Blood 113 22 2009 5617 5623
26. X. Xu, Q. Zhang, J. Luo, S. Xing, Q. Li, and S.B. Krantz JAK2(V617F): prevalence in a large Chinese hospital population Blood 109 1 2007 339 342
27. P. Sidon, H. El Housni, B. Dessars, and P. Heimann The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors Leukemia 20 9 2006 1622
28. B.L. Stein, D.M. Williams, N.Y. Wang, O. Rogers, M.A. Isaacs, and N. Pemmaraju Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders Haematologica 95 7 2010 1090 1097
29. D. Colaizzo, G.L. Tiscia, V. Bafunno, L. Amitrano, P. Vergura, and M.R. Lupone Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis Thromb Res 128 3 2011 233 236
30. M. Speletas, E. Katodritou, C. Daiou, E. Mandala, E. Papadakis, and A. Kioumi Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders Leuk Res 31 8 2007 1053 1062
31. C.H. Lieu, H.S. Wu, Y.C. Hon, W.H. Tsai, C.F. Yang, and C.C. Wang Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders Intern Med J 38 6 2008 422 426
32. T. Tadmor, E. Mishchenko, A. Polliack, and D. Attias Hookah (narghile) smoking: a new emerging cause of secondary polycythemia Am J Hematol 86 8 2011 719 720
33. I. Weinberg, A. Borohovitz, S. Krichevsky, R. Perlman, A. Ben-Yehuda, and D. Ben-Yehuda Janus kinase V617F mutation in cigarette smokers Am J Hematol 87 1 2012 5 8
34. E. Arellano-Rodrigo, A. Alvarez-Larran, J.C. Reverter, N. Villamor, D. Colomer, and F. Cervantes Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status Haematologica 91 2 2006 169 175
35. A. Falanga, M. Marchetti, A. Vignoli, D. Balducci, L. Russo, and V. Guerini V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules Exp Hematol 35 5 2007 702 711
36. A. Falanga, M. Marchetti, V. Evangelista, A. Vignoli, M. Licini, and M. Balicco Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera Blood 96 13 2000 4261 4266
37. V. De Stefano, T. Za, E. Rossi, A.M. Vannucchi, M. Ruggeri, and E. Elli Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments Haematologica 93 3 2008 372 380
38. R. Landolfi, R. Marchioli, J. Kutti, H. Gisslinger, G. Tognoni, and C. Patrono Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med 350 2 2004 114 124
39. K. Kaushansky The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age Best Pract Res Clin Haematol 20 1 2007 5 12
40. A. Tefferi, and J.W. Vardiman Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms Leukemia 22 1 2008 14 22